Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Advanced Solid Tumors 4Solid Tumors 2Solid Tumor 2Mesothelioma, Malignant 2Mesothelioma 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Solid Malignancy 1Relapsed Pediatric Solid Tumor 1Cholangiocarcinoma of the Gallbladder 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignant Solid Neoplasm 1Advanced Cancers 1Advanced Cancer 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumor × Everolimus × Other solid neoplasm × Clear all
NCT04185831 2024-08-22

MEGALiT

Uppsala University Hospital

Phase 2 Active not recruiting
167 enrolled
Other solid neoplasm

Solid Tumor

NCT02449538 2017-02-17

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Samsung Medical Center

Phase 2 Completed
10 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡